Comparing two blood thinners for left ventricle blood clots
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial compares the blood thinner apixaban to warfarin for treating blood clots in the main pumping chamber of the heart (left ventricle). The goal is to see which medicine is better at preventing strokes and other complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a blood clot in the left ventricle of your heart, confirmed by a special heart scan within the last 2 weeks.
- You are able to take a blood thinner for at least 3 months.
- You do not have a mechanical heart valve, certain heart valve conditions, or antiphospholipid syndrome.
- You do not have severe kidney or liver disease, active bleeding, or a very low platelet count.
- You are not pregnant or breastfeeding, and if you can become pregnant, you agree to use birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a newer blood thinner, apixaban, works better than the standard warfarin for treating blood clots in the left ventricle after a heart attack. The goal is to see which medication is safer and more effective at preventing complications.
This trial tests if patients with a blood clot in the left ventricle can safely stop blood thinner (Apixaban) after at least 3 months, instead of taking it longer. It may help people with no additional risks avoid extra medication.
This trial tests whether the blood thinner apixaban can prevent dangerous blood clots from forming in the heart's main pumping chamber after a specific type of heart attack. It is for patients who have severe weakness of the left ventricle and no clot already present.
This trial tests how to use a blood thinner in people after a recent heart attack who have a clot in the left heart chamber confirmed by heart MRI. It may help lower the risk of the clot causing serious complications, but it also requires careful bleeding-safety screening.
This trial studies whether taking blood thinners for longer helps people whose heart’s main pumping chamber (the left ventricle) has a blood clot. The goal is to see if it prevents further problems like strokes or clot growth.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
Hear when a new Left Ventricular Thrombus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.